Authors: Wu J, Zhou L, Liu J, et al.
Absolute 9.0% reduction in 28-day all-cause mortality (P=0.04)
In a multicenter, randomized, open-label trial across 6 intensive care units, 361 patients with severe sepsis were randomized to receive standard therapy or standard therapy plus subcutaneous thymosin alpha 1 (1.6 mg every 12 hours for 7 days). The primary endpoint was 28-day all-cause mortality. 28-day mortality was significantly lower in the thymosin alpha 1 group (26.0% vs. 35.0%, P=0.04), accompanied by accelerated recovery of mHLA-DR expression.
Multicenter randomized trial demonstrating that thymosin alpha-1 immunotherapy reduces 28-day all-cause mortality from 35.0% to 26.0% in patients with severe sepsis and immune paralysis.
* Educational commentary prepared by Peptide Health Digest editors to provide context on study methodology.
Wu J, Zhou L, Liu J, et al.
This study record was compiled from public biomedical repositories for educational and informational reference. Peptide Health Digest does not claim authorship of the original investigation.
